argenx upgraded by Robert W. Baird with a new price target
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Robert W. Baird upgraded argenx from Neutral to Outperform and set a new price target of $680.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2025 | $680.00 | Neutral → Outperform | Robert W. Baird |
| 3/17/2025 | Mkt Perform → Outperform | Bernstein | |
| 3/12/2025 | Sell → Hold | Deutsche Bank | |
| 1/17/2025 | Hold → Sell | Deutsche Bank | |
| 11/12/2024 | $697.00 | Peer Perform → Outperform | Wolfe Research |
| 11/5/2024 | $715.00 | Sector Perform → Sector Outperform | Scotiabank |
| 11/1/2024 | $515.00 → $650.00 | Outperform → Neutral | Robert W. Baird |
| 11/1/2024 | Mkt Perform → Outperform | William Blair |
6-K - ARGENX SE (0001697862) (Filer)
6-K - ARGENX SE (0001697862) (Filer)
6-K - ARGENX SE (0001697862) (Filer)
SC 13G/A - ARGENX SE (0001697862) (Subject)
SC 13G/A - ARGENX SE (0001697862) (Subject)
SC 13G/A - ARGENX SE (0001697862) (Subject)
May 28, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025. 91.1% of the Company's share capital was represented at the Annual General Meeting. All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a 73.0% majority where a 75% majority was required. As part of the approved resolutions: The Company's 2024 remuneration report received a 76.7% majo
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V
May 6, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation. About argenx argenx is a global immunology company committ
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V
May 1, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium 32 800 50 201France
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering f
January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f
December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
September 8, 2022 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.arg
Robert W. Baird upgraded argenx from Neutral to Outperform and set a new price target of $680.00
Bernstein upgraded argenx from Mkt Perform to Outperform
Deutsche Bank upgraded argenx from Sell to Hold